Display Settings:

Format

Send to:

Choose Destination
Clin Ophthalmol. 2008 Dec;2(4):693-702.

A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin.

Author information

  • 1Lux Biosciences Inc., Harborside Financial Center, Plaza 10, 14th Floor, Jersey City, NJ, USA. eddy.anglade@luxbio.com

Abstract

Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Currently available therapies are burdened with toxicities and/or lack definitive evidence of efficacy. Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile, a strong correlation between pharmacokinetic and pharmacodynamic response, and a wide therapeutic window. The LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) clinical development program was initiated in 2007 to assess the safety and efficacy of voclosporin for the treatment, maintenance, and control of all forms of noninfectious uveitis. If LUMINATE is successful, voclosporin will become the first Food and Drug Administration-approved corticosteroid-sparing agent for this condition.

KEYWORDS:

ISA247; LUMINATE trials; LX211; calcineurin inhibitors; ophthalmic diseases; uveitis; voclosporin

PMID:
19668418
[PubMed]
PMCID:
PMC2699819
Free PMC Article

Images from this publication.See all images (4)Free text

Figure 2
Figure 3
Figure 4
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk